Bard IVC (inferior vena cava) Filters have protected thousands of patients at risk of recurrent pulmonary embolism who otherwise would have had limited treatment options. Preventing this life-threatening condition is in the best interest of patients and healthcare providers around the world.
Vena cava filters are implanted by physicians only after careful consideration of the risks and benefits of the device in light of each patient’s condition. When used as instructed, Bard IVC Filters demonstrate significant benefits to patients and have a safety profile consistent with the medical guidelines published by the American College of Radiology (ACR) and Society of Interventional Radiology (SIR).
Sr. VP, Science, Tech & CA
Background on Bard’s Vena Cava Filters
- Vena cava filters have been used by the medical community in the United States since the 1960s. C. R. Bard first obtained FDA clearance to market these devices more than a decade ago.
- Bard IVC Filters undergo a thorough battery of testing in compliance with federal law, and are evaluated by FDA before reaching the market.
- Publication of the clinical data on the Bard Denali® Vena Cava Filter received a Clinical Study Editor’s Honoree Award for 2014 voted on by the editorial board and selected by the editor-in-chief of the Journal of Vascular and Interventional Radiology (JVIR) for best-in-class research.
- Bard puts the interests of patients first. As part of this commitment, we conduct education and outreach to physicians and hospitals to help ensure the safe and appropriate use of our filters.
For more information, including important safety information, click here